The primary goal of thos study is to assess safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation (Phase I - Clinical trial). Following allogeneic BMT, patients will be placed on standard GVHD preventive therapy (cyclosporine). Secondary goals - * monitoring immune system recovery * the influence of stem cells origin on therapy and/orGVHD prevention * the influence of UV-c treatment on survival clinical data and samples will be collected, during UV-c therapy, 100 days after discharge \& 6 months after discharge - to examine the long-term effect of UV-c treatment on the patient's GVHD status.
Treatment will be given with a portable, easy to operate device named "EUMATRON". this device contains a UV- lamp. 250 cc of blood from a peripheric vein is going through the device into a bottle with Low dose Heparin and returning to patient's body. procedure takes \~20 minutes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
Hadassah Medical Organization
Jerusalem, Israel
safety and tolerability of UV-c phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation
Time frame: 6 months
monitoring immune system recovery, influence on survival rates, influence of stem cells origin on treatment & prevention of GVHD
Time frame: 100 days, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.